Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ODAC To Assess Schering's PegIntron and GSK's Votrient In October

This article was originally published in The Pink Sheet Daily

Executive Summary

The committee will discuss PegIntron for melanoma, and Votrient for renal cell carcinoma.

You may also be interested in...



Pfizer Reports Sutent Safe And Effective In Asians, Forges Alliances With Major Asian Oncology Centers

Pfizer may draw on Sutent research centers for trials on other oncology therapies such as axitinib and figitumumab, an insulin growth factor receptor inhibitor.

Pfizer Reports Sutent Safe And Effective In Asians, Forges Alliances With Major Asian Oncology Centers

Pfizer may draw on Sutent research centers for trials on other oncology therapies such as axitinib and figitumumab, an insulin growth factor receptor inhibitor.

Arzerra Disappoints In NHL, Putting Genmab On Shaky Ground

Genmab and partner GlaxoSmithKline reported August 17 disappointing top-line results from a Phase II study of their anti-CD 20 antibody Arzerra in rituximab-refractory follicular non-Hodgkin's lymphoma, calling into question the biotech's future as an independent entity

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel